… Heart Association functional classes II to IV, structural heart … of both valsartan (80 mg twice
daily) and sacubitril/valsartan (… with valsartan 160 mg twice daily or sacubitril/valsartan 97/103 …

… change in atrial natriuretic peptide (ANP) and reverse cardiac remodeling following
initiation of sacubitril/valsartan in patients with heart failure with reduced ejection fraction (HFrEF). …

… Sacubitril/valsartan reduced heart failure (HF) admissions and cardiovascular mortality in the
… and safety of the drug in an advanced heart failure cohort and to review systematically the …

… -valsartan use reduces mortality and hospitalizations compared with enalapril among patients
with chronic heart failure … initiation of sacubitril-valsartan vs enalapril compared with no …

… failure mortality and reversing left atrial remodeling, … type of heart failure, subjects that used
sacubitril/valsartan manifested an … NT-proBNP holds significance in predicting heart failure …

… the efficacy of valsartan combined with trimetazidine in the treatment of chronic heart failure
(CHF) … Patients in the control group were treated with valsartan (80 mg/time, 1 time/d), while …

… par l’association sacubitril-valsartan au Canada. Sous cet … Canadians are currently living
with heart failure (HF), and … ARNI), sacubitril/valsartan, has demonstrated superior efficacy …

… Sacubitril/valsartan … chronic heart failure (New York Heart Association [NYHA] class II–IV)
and reduced ejection fraction [14]. In the PARADIGM-HF trial, treatment with sacubitril/valsartan …

… ) sacubitril-valsartan in patients with heart failure with preserved … and safety of sacubitril-valsartan
in patients with HFpEF … New York Heart Association (NYHA) class II–IV heart failure, …

… -valsartan reduces cardiovascular mortality and heart failure hospitalization in patients
with heart failure and … Objective To determine whether treatment of HFrEF with sacubitril-valsartan …